Compare Stocks: YARW, INO, OTLK, and COYA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COYA Coya Therapeutics	$5.04 +1.6%	$4.90	$3.71 ▼ $7.75	$118.23M	0.6	188,509 shs	145,184 shs
INO Inovio Pharmaceuticals	$1.29 +3.2%	$1.04	$0.56 ▼ $2.98	$133.38M	1.52	2.54 million shs	3.60 million shs
OTLK Oncobiologics	$0.64 +5.1%	$1.26	$0.16 ▼ $3.39	$95.10M	0.82	13.74 million shs	15.92 million shs
YARW Yarrow Bioscience	$39.25 -0.6%	$0.00	$14.02 ▼ $46.95	$105.45M	1.95	12,987 shs	9,293 shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COYA Coya Therapeutics	+1.85%	+6.21%	+16.71%	+5.31%	-27.70%
INO Inovio Pharmaceuticals	+5.93%	+8.70%	+28.85%	-0.79%	-36.22%
OTLK Oncobiologics	-5.90%	-9.40%	-56.65%	+52.17%	-77.28%
YARW Yarrow Bioscience	+8.46%	-4.59%	+3,949,999,900.00%	+3,949,999,900.00%	+3,949,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COYA Coya Therapeutics	$5.04 +1.6%	$4.90	$3.71 ▼ $7.75	$118.23M	0.6	188,509 shs	145,184 shs
INO Inovio Pharmaceuticals	$1.29 +3.2%	$1.04	$0.56 ▼ $2.98	$133.38M	1.52	2.54 million shs	3.60 million shs
OTLK Oncobiologics	$0.64 +5.1%	$1.26	$0.16 ▼ $3.39	$95.10M	0.82	13.74 million shs	15.92 million shs
YARW Yarrow Bioscience	$39.25 -0.6%	$0.00	$14.02 ▼ $46.95	$105.45M	1.95	12,987 shs	9,293 shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COYA Coya Therapeutics	+1.85%	+6.21%	+16.71%	+5.31%	-27.70%
INO Inovio Pharmaceuticals	+5.93%	+8.70%	+28.85%	-0.79%	-36.22%
OTLK Oncobiologics	-5.90%	-9.40%	-56.65%	+52.17%	-77.28%
YARW Yarrow Bioscience	+8.46%	-4.59%	+3,949,999,900.00%	+3,949,999,900.00%	+3,949,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COYA Coya Therapeutics	2.71	Moderate Buy	$15.33	204.23% Upside
INO Inovio Pharmaceuticals	2.75	Moderate Buy	$3.17	145.48% Upside
OTLK Oncobiologics	2.14	Hold	$4.65	626.56% Upside
YARW Yarrow Bioscience	3.00	Buy	$58.00	47.77% Upside

Current Analyst Ratings Breakdown

Latest YARW, INO, OTLK, and COYA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/24/2026	COYA Coya Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/24/2026	COYA Coya Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$12.00
8/14/2026	OTLK Oncobiologics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$4.00
8/13/2026	INO Inovio Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/13/2026	INO Inovio Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
8/13/2026	INO Inovio Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Positive	$1.80 ➝ $3.00
8/12/2026	OTLK Oncobiologics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/12/2026	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$14.00
8/12/2026	INO Inovio Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/3/2026	INO Inovio Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$4.00
8/3/2026	YARW Yarrow Bioscience	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold ➝ Buy	$58.00

(Data available from 8/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COYA Coya Therapeutics	$8.02M	14.74	N/A	N/A	$2.06 per share	2.45
INO Inovio Pharmaceuticals	N/A	N/A	N/A	N/A	$0.36 per share	N/A
OTLK Oncobiologics	$1.35M	70.44	N/A	N/A	($0.60) per share	-1.07
YARW Yarrow Bioscience	$570K	183.86	N/A	N/A	$41.71 per share	0.94

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COYA Coya Therapeutics	-$21.23M	-$1.07	N/A	N/A	N/A	-270.22%	-52.05%	-46.34%	11/11/2026 (Estimated)
INO Inovio Pharmaceuticals	-$84.95M	-$0.91	N/A	N/A	N/A	N/A	-669.94%	-73.97%	11/10/2026 (Estimated)
OTLK Oncobiologics	-$62.42M	-$0.77	N/A	N/A	N/A	N/A	N/A	-254.82%	N/A
YARW Yarrow Bioscience	-$26.48M	-$14.64	N/A	N/A	N/A	-4,726.21%	-84.40%	-77.68%	N/A

Latest YARW, INO, OTLK, and COYA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q3 2026	OTLK Oncobiologics	-$0.08	-$0.09	-$0.01	-$0.15	$0.97 million	$0.01 million
8/12/2026	Q2 2026	INO Inovio Pharmaceuticals	-$0.2167	-$0.07	+$0.1467	-$0.07	$0.53 million	N/A
8/11/2026	Q2 2026	COYA Coya Therapeutics	-$0.3457	-$0.28	+$0.0657	-$0.28	$0.13 million	$0.24 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
COYA Coya Therapeutics	N/A	N/A	N/A	N/A	N/A
INO Inovio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
OTLK Oncobiologics	N/A	N/A	N/A	N/A	N/A
YARW Yarrow Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COYA Coya Therapeutics	N/A	13.40	13.40
INO Inovio Pharmaceuticals	N/A	1.00	1.00
OTLK Oncobiologics	N/A	0.81	0.63
YARW Yarrow Bioscience	N/A	15.26	15.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COYA Coya Therapeutics	39.75%
INO Inovio Pharmaceuticals	26.79%
OTLK Oncobiologics	11.20%
YARW Yarrow Bioscience	83.78%

Insider Ownership

Company	Insider Ownership
COYA Coya Therapeutics	6.10%
INO Inovio Pharmaceuticals	1.70%
OTLK Oncobiologics	1.80%
YARW Yarrow Bioscience	3.03%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COYA Coya Therapeutics	6	23.46 million	22.03 million	Not Optionable
INO Inovio Pharmaceuticals	320	103.40 million	101.64 million	Optionable
OTLK Oncobiologics	20	148.59 million	145.91 million	Optionable
YARW Yarrow Bioscience	30	2.67 million	2.59 million	N/A

YARW, INO, OTLK, and COYA Headlines

Recent News About These Companies

Wall Street Zen Upgrades Yarrow Bioscience (NASDAQ:YARW) to "Hold"

August 22 at 1:13 AM | americanbankingnews.com

Analyst Maintains Buy on Yarrow Bioscience, Sees Attractive Risk-Reward with Unchanged $56 Price Target

August 13, 2026 | tipranks.com

Yarrow Bioscience Alters Capital Structure With Warrant Exchange

July 30, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

YARW, INO, OTLK, and COYA Company Descriptions

Coya Therapeutics NASDAQ:COYA

$5.04 +0.08 (+1.61%)

Closing price 04:00 PM Eastern

Extended Trading

$5.06 +0.02 (+0.40%)

As of 04:24 PM Eastern

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

Inovio Pharmaceuticals NASDAQ:INO

$1.29 +0.04 (+3.20%)

Closing price 04:00 PM Eastern

Extended Trading

$1.26 -0.03 (-1.94%)

As of 05:37 PM Eastern

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Oncobiologics NASDAQ:OTLK

$0.64 +0.03 (+5.09%)

Closing price 04:00 PM Eastern

Extended Trading

$0.64 +0.01 (+0.78%)

As of 05:43 PM Eastern

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Yarrow Bioscience NASDAQ:YARW

$39.25 -0.25 (-0.63%)

Closing price 04:00 PM Eastern

Extended Trading

$39.28 +0.02 (+0.06%)

As of 05:29 PM Eastern

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest YARW, INO, OTLK, and COYA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest YARW, INO, OTLK, and COYA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

YARW, INO, OTLK, and COYA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

YARW, INO, OTLK, and COYA Company Descriptions

Coya Therapeutics NASDAQ:COYA

Inovio Pharmaceuticals NASDAQ:INO

Oncobiologics NASDAQ:OTLK

Yarrow Bioscience NASDAQ:YARW

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest YARW, INO, OTLK, and COYA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest YARW, INO, OTLK, and COYA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

YARW, INO, OTLK, and COYA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

YARW, INO, OTLK, and COYA Company Descriptions

Coya Therapeutics NASDAQ:COYA

Inovio Pharmaceuticals NASDAQ:INO

Oncobiologics NASDAQ:OTLK

Yarrow Bioscience NASDAQ:YARW

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools